Development and Implementation of Intensified Bioprocessing for Biologics Manufacturing


12th March 2021 | 15:30 CST | Hang Zhou, Ph.D., Vice President, Head of Cell Culture Process Development Biologics and Bioprocess Dept. at WuXi Biologics |BOOK FREE SEAT FOR THIS WEBINAR

There are increasing needs for flexibility and speed in bioprocessing, as well as lower Cost of Goods in biologics manufacturing. In order to accelerate biologics development and manufacturing as well as to improve affordability of biologics, WuXi Biologics developed a proprietary biologics production platform, WuXiUP, with Ultra-high Productivity. With WuXiUP the cell culture has achieved productivity of 2.5g/L/day and 51g/L bioreactor volume in a 20-day process for an Fc-fusion protein. The Platform enables almost any biologics, including mAbs and fusion proteins, to be manufactured at ultra-high productivity. The intensified and continuous cell culture process can be rapidly developed or converted from traditional fed-batch process with excellent scalability and robustness. This next generation biologic manufacturing solution enables 1,000-2,000L disposable bioreactors to achieve similar productivity as traditional 10,000-20,000L stainless bioreactors, which will expedite product launch and significantly reduce the Cost of Goods of a commercial product.

Presented by Hang Zhou, Ph.D., Vice President, Head of Cell Culture Process Development Biologics and Bioprocess Dept. at WuXi Biologics

Dr. Hang Zhou studied Biotechnology and received his PhD in Chemical Engineering from Massachusetts Institute of Technology. He has more than 10 years of experience in cell culture process development, in particular continuous processing.
At WuXi Biologics Hang leads a team in continuous cell culture process development for biologics. His team successfully overcame multiple challenges accompanied with intensified perfusion culture, and developed WuXiUP, a proprietary biologics production platform with Ultra-high Productivity. With WuXiUP the cell culture has achieved productivity of 2.5g/L/day and 51g/L bioreactor volume in a 20-day process for an Fc-fusion protein. The Platform enables almost any biologics, including mAbs and fusion proteins, to be manufactured at ultra-high productivity. The intensified and continuous cell culture process can be rapidly developed or converted from traditional fed-batch process with excellent scalability and robustness. It’s also couples with continuous column chromatography, which enables a similar purification yield of traditional purification process.

Prior to joining WuXi Biologics, Dr. Zhou worked for Commercial Cell Culture Development at SANOFI GENZYME and led efforts in the next-generation perfusion platform development.

Sponsored by Repligen

Inspiring advances in bioprocessing, Repligen is a technology leader in filtration, chromatography, systems, process analytics and Protein A ligand development for bioprocessing and gene therapy. Propelled by a culture of innovation and collaboration, and with a focus on cost and process efficiencies, our people and our technologies help address critical steps in the production of therapeutics, vaccines and diagnostics worldwide. Named one of the fastest growing biotech companies in the USA, Repligen is headquartered in Boston, MA with major manufacturing sites in Massachusetts, California, New Jersey, Sweden, and Germany.


We will not sell your information to a third party. See our Privacy Policy